Loading...
01/11 07:57
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: revenue has decreased, and there are uncertainties in NIH funding, but there is optimism about product launches and market opportunities. The Q&A reveals management's evasiveness on key issues, adding uncertainty. Despite financial constraints, cost controls are evident. Strong financial metrics are offset by weak guidance and lack of clarity, leading to a neutral sentiment.
Revenue (Q3 2025) $552,000, a decrease year-over-year due to capital market headwinds and NIH funding uncertainty.
Gross Profit (Q3 2025) $194,000, with a gross margin of 35%. Gross margin variability is attributed to commercialization efforts and inventory accounting adjustments.
Revenue (9 months ended September 30, 2025) $2.0 million, impacted by capital market headwinds and NIH funding challenges.
Gross Profit (9 months ended September 30, 2025) $1.0 million, with a gross margin of 52%.
GAAP Total Operating Expenses (Q3 2025) $40 million, compared to $28.5 million in Q3 2024. Increase due to a $13.6 million accounting adjustment related to lease termination.
Adjusted Operating Expenses (Q3 2025) $21.4 million, compared to $26.0 million in Q3 2024, reflecting tight cost controls.
GAAP Total Operating Expenses (9 months ended September 30, 2025) $96 million, compared to $78.9 million in the same period in 2024. Increase due to lease termination adjustments.
Adjusted Operating Expenses (9 months ended September 30, 2025) $68.1 million, compared to $72.3 million in the same period in 2024, reflecting cost control measures.
Dividend and Interest Income (Q3 2025) $2.6 million, compared to $2.7 million in Q3 2024, reflecting lower interest rates and invested balances.
Dividend and Interest Income (9 months ended September 30, 2025) $7.4 million, compared to $9.1 million in the same period in 2024, due to lower interest rates and invested balances.
Cash, Cash Equivalents, and Investments (as of September 30, 2025) $230.5 million, reflecting the company's financial position.
Proteus system prototype sequencing runs: Successfully completed sequencing runs on a prototype Proteus system, achieving a major milestone for 2025. Multiple prototypes are performing sequencing with improving data quality.
Version 4 sequencing kit: Launched commercially in early September, featuring increased amino acid detection capabilities, a new enzyme for high-efficiency cutting, and expanded barcodes for higher multiplexing.
Version 3 library preparation kit: Entered internal validation, on track for launch by end of 2025. Reduces sample input requirement by 100-fold, enabling broader biological sample processing.
Amino acid recognizer development program: Leveraging proprietary data and AI tools to accelerate development and shorten timelines for full proteome coverage.
Placement program: 12 new customers implemented the platform, with over half in academic labs despite NIH funding challenges. Broad Institute initiative progressing with active projects and educational seminars.
Proteomics market opportunity: Confident in long-term market potential and initiatives to grow installed base and capitalize on opportunities.
Revenue and gross margin: Q3 2025 revenue was $552,000 with a gross margin of 35%. Year-to-date revenue was $2.0 million with a gross margin of 52%.
Cost controls: Adjusted operating expenses decreased year-over-year, highlighting tight cost management while funding innovation.
Lease termination: Terminated New Haven lease, saving over $24 million in future operating expenses.
Strategic partnerships: Exploring partnerships to accelerate development in customer applications, sample preparation, and AI-driven insights.
Capital market positioning: Filed a $300 million shelf registration and $100 million ATM facility to support strategic initiatives and maintain financial strength.
Capital Sales Headwinds: Revenue for the third quarter was significantly impacted by capital sales headwinds in the market, particularly due to challenges in NIH funding, which has made it difficult to access academic labs.
NIH Funding Challenges: The company faced difficulties in accessing academic labs due to reduced NIH funding, which has negatively impacted revenue and market penetration.
Gross Margin Variability: Gross margin percentage is expected to remain variable due to continued commercialization efforts and the timing and mix of instruments versus consumable sales.
Operating Expenses: GAAP total operating expenses increased significantly year-over-year, driven by a $13.6 million accounting adjustment related to a lease termination and other operational costs.
Lease Termination Costs: The company incurred a $10.2 million cash outlay for the termination of a lease in New Haven, Connecticut, which, while saving future expenses, impacted short-term financials.
Capital Market Uncertainty: Uncertainty in the capital market has impacted the company’s ability to generate revenue and has created challenges for commercialization efforts.
Proteus Platform Development Risks: While progress has been made on the Proteus platform, the optimization of sequencing chemistry and data quality improvements remain ongoing challenges.
Library Preparation Kit Development: The development of the version 3 library preparation kit, which aims to lower sample input requirements, is still in the validation process and has not yet been launched.
Dependence on Consumable Sales: The company’s revenue model increasingly depends on consumable sales, which may be impacted by the adoption rate of its installed base.
Regulatory and Market Risks: The company faces risks related to regulatory compliance and market acceptance of its new products and technologies.
Revenue Expectations: The company expects continued impact on short-term commercial results due to capital market headwinds but is optimistic about the early traction seen with the placement program. The placement program is expected to grow the customer base and drive consumable sales.
Proteus Platform Development: The company has successfully completed sequencing runs on a prototype Proteus system, achieving a key milestone for 2025. Multiple prototype systems are performing sequencing, and data quality is expected to improve as the platform matures. Updates will be shared at the Investor and Analyst Day on November 19.
Version 3 Library Preparation Kit: The kit is in internal validation and on track for launch by the end of 2025. It is expected to lower sample input quantity requirements by at least 100-fold, enabling broader biological sample processing and improved system performance.
Version 4 Sequencing Kit: Commercially launched in early September 2025, the kit includes increased amino acid detection capabilities and expanded barcoding options, enhancing multiplexing levels for experiments.
Amino Acid Recognizer Development Program: The program leverages a proprietary dataset and advanced AI tools to scale up development and shorten timelines for full proteome coverage. More details will be shared on November 19.
Financial Guidance: Adjusted operating expenses for 2025 are expected to be $96 million or less, with total cash use projected at $103 million or less. The company has a strong balance sheet with $230.5 million in cash, cash equivalents, and investments as of September 30, 2025.
Dividend and Interest Income: In the third quarter of 2025, dividend and interest income was $2.6 million compared to $2.7 million in the third quarter of 2024. For the 9 months ended September 30, 2025, it was $7.4 million compared to $9.1 million in the same period in 2024. This change reflects lower interest rates year-over-year as well as relatively lower invested balances.
Share Sales and Ownership: Management and Board collectively held approximately 18% of the total outstanding stock of Quantum-Si. Share sales by management team members were limited to mandatory redemptions to cover taxes for vested restricted shares. No ongoing reporting management team member sold company stock outside these mandatory redemptions for 2023, 2024, and 2025 year-to-date.
The earnings call presents mixed signals: revenue has decreased, and there are uncertainties in NIH funding, but there is optimism about product launches and market opportunities. The Q&A reveals management's evasiveness on key issues, adding uncertainty. Despite financial constraints, cost controls are evident. Strong financial metrics are offset by weak guidance and lack of clarity, leading to a neutral sentiment.
The earnings call summary and Q&A reveal strong financial performance with an 84% revenue increase and a 58% gross margin. Management is optimistic about growth, especially in Q4, and is implementing flexible sales models to overcome capital constraints. The company is focused on innovation and market expansion, particularly in pharma and biotech. Despite some unclear responses, the overall sentiment is positive, supported by strategic product launches and a solid cash position. The stock price is likely to experience a positive movement in the next two weeks.
The earnings call reveals mixed signals: strong revenue growth and international expansion are positive, but uncertainties in NIH funding and a slowdown in the U.S. academic market are concerning. The Q&A session highlights confidence in the biopharma market and positive feedback on product launches, but unclear responses on tariffs and a dip in dividend income raise caution. With a robust cash position and strategic partnerships, the short-term stock reaction is likely neutral, balancing positive growth against market uncertainties.
The earnings call reveals mixed signals: strong revenue growth and international expansion are positive, but uncertainties in the U.S. academic market and regulatory issues create concerns. The Q&A highlighted management's confidence in partnerships and product launches, yet avoided specifics on tariff impacts. Financials show increased revenue but lower-than-expected results due to market slowdowns. The strong cash position is reassuring, but dividend income decline is negative. Overall, the sentiment balances out to neutral, with no extreme factors to drive significant stock movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
